BrainStorm Live Episode 13: How Amprion Enables Early Detection of Neurodegenerative Diseases
Amprion’s CEO Dr. Russ Lebovitz explains how Amprion’s groundbreaking technology can detect tiny soluble misfolded protein aggregates of Abeta, Tau, and Synuclein–three biomarkers (aka Prions) known to cause Alzheimer’s, Parkinson’s and other neurodegenerative diseases. These soluble misfolded protein aggregates represent the earliest molecular footprints of neurodegenerative disease and may also represent the actively growing forms of the disease. Through its revolutionary Prion Early Detection Science℠, Amprion offers a 20/20 vision in tracking the bad actors that drive the progression of Alzheimer’s, Parkinson’s and other neurodegenerative diseases. Accurate early detection is the keystone in finding effective treatments, and Amprion’s breakthrough science can accelerate successful drug development for Alzheimer’s and Parkinson’s.
Early & Sensitive Prion Detection
Clearly we have data that we can detect years ahead and we suspect that we can detect even decades ahead. And the reason for that is just again to recap that the major neurodegenerative diseases seem to be initiated by misfolding of normal brain proteins into unusual aggregated structures, meaning they stick together. When it first, when misfolding begins to appear, one can first form small, soluble aggregates that are invisible under the microscope, invisible to imaging technologies. But these are the earliest forms of the disease that lead to spreading from a single cell to multiple cells. Once these are formed, the disease has begun. Since these are invisible to all existing technologies except Amprion’s technology, Amprion’s ability to detect the small, soluble aggregates soon after they begin to form and spread is the hallmark of early detection and it is necessary for early detection. Amprion pioneers in early detection of prions to detect the earliest progression of Alzheimer’s and Parkinson’s.
Spread the Word. Join The Fight. #JTFBrainHealth